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Abstract
The nature of the interaction between replicating HIV-1 and the cellular RNAi pathway has been controversial, but it is clear
that it can be complex and multifaceted. It has been proposed that the interaction is bi-directional, whereby cellular
silencing pathways can restrict HIV-1 replication, and in turn, HIV-1 can suppress silencing pathways. Overall suppression of
RNAi has been suggested to occur via direct binding and inhibition of Dicer by the HIV-1 Tat protein or through
sequestration of TRBP, a Dicer co-factor, by the structured TAR element of HIV-1 transcripts. The role of Tat as an inhibitor of
Dicer has been questioned and our results support and extend the conclusion that Tat does not inhibit RNAi that is
mediated by either exogenous or endogenous miRNAs. Similarly, we find no suppression of silencing pathways in cells with
replicating virus, suggesting that viral products such as the TAR RNA elements also do not reduce the efficacy of cellular
RNA silencing. However, knockdown of Dicer does allow increased viral replication and this occurs at a post-transcriptional
level. These results support the idea that although individual miRNAs can act to restrict HIV-1 replication, the virus does not
counter these effects through a global suppression of RNAi synthesis or processing.
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Introduction
RNA interference (RNAi) is an evolutionarily conserved
mechanism of sequence dependent gene regulation that can have
a role in host cell defense against intracellular pathogens and
transposons. RNAi can be essential for antiviral defense in plants
and lower eukaryotes (reviewed in [1]); however, in higher
eukaryotes, innate immune mechanisms such as those mediated
through interferons and Toll-like receptor pathways are promi-
nent, leading to questions regarding the antiviral role of RNAi in
these organisms. Nevertheless, RNAi has been implicated in
restricting the replication of various mammalian viruses including
HBV [2,3], influenza A [4], and HIV-1 [5], among others.
In plants, the global suppression of RNAi by virally encoded
proteins is a common countermeasure to host antiviral mechanisms
mediatedbyRNAsilencing[6],andsimilarsuppressionmechanisms
have been proposed for several mammalian viruses [7,8]. With
regard to HIV-1 in particular, the HIV-1 Tat protein was reported
tosuppressRNAithroughadirect,RNA-dependentinteractionwith
and inhibition of Dicer [9,10] or, alternatively, through the
sequestration of mature miRNAs [11]. In addition, it has been
suggested thatbindingofthe cellular proteinTRBPtothe structured
TAR elements present in HIV-1 transcripts competitively inhibits
the activity of TRBP as a co-factor for Dicer, leading to a down-
regulation of miRNA processing pathways [12,13]. The notion that
HIV-1 has evolved gene products that are able to globally suppress
RNAi in order to promote its own replication has remained
controversial and evidence has been presented that Tat acts only in
its well-characterized role as a transcriptional activator, and does not
suppress RNA silencing [14].
Multiple lines of evidence have shown that interactions between
HIV-1 and cellular RNAi pathways can not only restrict HIV-1
replication but can also promote viral latency [15,16,17,18,19].
Both bioinformatics and functional studies have indicated that
cellular miRNAs can affect HIV-1 replication, either through
direct targeting of viral RNAs [15,16,17,18,19] or through
targeting of cellular RNAs necessary for viral replication [5,20].
Further, HIV-1 transcripts have been co-localized with RNAi
effector proteins in P-bodies [18,21], and, it has been shown that
knockdown of several proteins of the miRNA processing pathway,
including Dicer, Drosha, and DGCR8, leads to an increase in viral
replication [5,18]. While these results support the idea that global
suppression of RNAi pathways would benefit the virus, there is
also evidence indicating that HIV-1 infection, or even direct
treatment of cells with Tat, is not accompanied by an overall
down-regulation of miRNA expression, and instead, a more
complex cellular response leads to the up- or down- regulation of
individual miRNAs [5,22,23,24]. In addition, HIV-1 has been
successfully targeted by artificial shRNA and miRNA-based
approaches (reviewed in [25,26]) and long-term expression of
therapeutic interfering RNAs has been observed in HIV-1 infected
cells [27], again arguing against a significant reduction in the
RNAi capacity of infected cells. While HIV-1 can escape
therapeutic interfering RNAs, this has been attributed to
mutations that occur in or near the target region and not to
generalized inhibition of RNAi [28,29].
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replication on cellular physiology in the search for vulnerabilities
where antiviral therapies may be directed, including RNAi-based
therapies, we have re-evaluated the potential for HIV-1 to suppress
the cellular RNAi machinery. We confirm that viral replication can
be limited at a post-transcriptional level by a Dicer-dependent
mechanism, suggesting that the activity of certain miRNAs can
reduce viral replication. However, using several measures of
miRNA function and processing, we find no evidence that the
virus counters these effects by suppressing RNAi through the
activity of products of viral replication, including Tat and TAR.
Results
HIV-1 Tat protein as a suppressor of RNA silencing
mediated by exogenously expressed miRNA
In order to understand the role of RNAi in cellular defense
mechanisms against HIV-1, we first tried to confirm findings
indicating that the viral Tat protein acts as a suppressor of RNA
silencing (SRS). In experiments modeled after those reported by
Bennasser et al. [9], we asked whether silencing of an EGFP
reporter by EGFP- miRNA could be suppressed by co-expression
of Tat protein. P4R5 cells, an HIV-1 reporter cell line derived
from HeLa cells [30], were co-transfected with pdsEGFP and a
plasmid encoding miEGFP, in the presence or absence of a Tat
expression plasmid, pwtTat. As shown in Figure 1A and B, lanes 1
and 2, miEGFP was able to silence EGFP expression by
approximately 80% in the absence of co-expressed Tat. In
agreement with the results of Bennasser et al. [9], co-transfection
with pwtTat appeared to suppress that silencing and restored
EGFP expression to as much as 75% of untreated values at the
highest dose (Figure 1A and B, lanes 3 and 4). However, two
additional results cast doubt on the interpretation that Tat is acting
to suppress silencing. First, when cells were co-transfected with
pTat-K41A, a plasmid that encodes a transcriptionally inactive
Tat mutant ([31] and see Figure S1), there was no rescue of EGFP
expression (Figure 1A and B, lanes 5 and 6). This is in contrast to
the observation by Bennasser et al. that the Tat-K41A mutant,
while transcriptionally inactive, retained the ability to suppress
RNA silencing [9]. Second, when cells were transfected with
pwtTat in the absence of the silencing plasmid, p7SK-miEGFP, it
was evident that Tat alone can substantially increase the
expression of the EGFP reporter (Figure 1A and B, lanes 7 and
8). Expression of the mutant K41A Tat did not affect EGFP levels
Figure 1. The effect of Tat over-expression on the silencing potency of miEGFP. (A) Immunoblot analysis of protein extracts obtained from
P4R5 cells 2 days post-transfection with indicated plasmids. The blot was analyzed using antibodies specific to EGFP and b-actin, which serves as a
loading control. (B) Spot-densitometry analysis of two individual experiments, as described in (A). The data are shown as the ratio of EGFP to b-actin
and presented as the percentage of control (no miEGFP, no Tat). Error bars represents standard deviation from 3 replicates. (C) Total RNA was
extracted from cells transfected in (A) and, following DNase treatment, qRT-PCR was performed to quantitate EGFP mRNA. The data are normalized to
b-actin and presented as fold change over control (no miEGFP). Error bars represent standard deviation from 3 replicates. (D) Lower panel: the RNA
preparation from (C) was subjected to primer extension reaction to detect mature miEGFP. Upper panel: U6 RNA was detected by northern blotting
to confirm RNA integrity and quantification.
doi:10.1371/journal.pone.0017246.g001
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relationship between the transcriptional activity of Tat and its
ability to up-regulate EGFP reporter expression, in a manner
independent of silencing. To test further whether Tat expression
up-regulates EGFP at the level of transcription rather than acting
as an SRS, we used quantitative RT-PCR (qRT-PCR) to
determine the level of EGFP mRNA in transfected cells from
the experiment shown in Figure 1A. The results (Figure 1C) again
indicate that Tat alone (in the absence of miEGFP) is acting to
increase the level of EGFP mRNA, likely accounting for the
increase in EGFP protein seen in cells co-transfected with the
silencing plasmid, pmiEGFP, and pwtTat. These results are
consistent with those reported by Lin and Cullen, who also argued
against a role for Tat as a global suppressor of RNA silencing [14].
In the original report of SRS activity for Tat, evidence was
presented indicating that Tat functioned by inhibiting Dicer
[9,10]. Therefore, we investigated the effect of Tat expression on
the maturation of co-expressed miEGFP. Mature miEGFP, the
product of Dicer cleavage of pre-miRNA [32], was assayed by
primer extension of RNA isolated in Figure 1B and results are
shown in Figure 1D. We found no evidence of reduced processing
of pre-miEGFP in the presence of either wtTat or K41A-Tat
overexpression. Control experiments showed that knockdown of
Dicer by transfection of an miDicer expression plasmid resulted in
reduced levels of mature miEGFP in this assay (see Figure S2).
TheexperimentsreportedaboveusedtheHeLa-derivedP4R5cell
line, although the original report of Tat SRS activity used HeLa cells
[9]. When we repeated the experiments in HeLa cells, we obtained
very similar results to those seen with the P4R5 cells (see Figure S3).
Taken together, our results support the conclusion that the apparent
ability of Tat to counter the effects of silencing by miEGFP can be
explained by its function as a transcriptional activator, without
invoking inhibition of Dicer or suppression of silencing.
HIV-1 Tat protein as a suppressor of RNA silencing by
endogenous miRNAs
In order to test the effects of Tat expression on the activity of an
endogenous cellular miRNA, we used a dual luciferase reporter
vector, psiCHECK-2, with target sequence perfectly complemen-
tary to human miR-16 inserted into the 39UTR of the Renilla
luciferase (Rluc) expression cassette. The reporter plasmid,
psiCH2-16T, was transfected into HeLa cells in the presence or
absence of wtTat or K41A-Tat expression plasmid. Figure 2 shows
that insertion of the miR-16 target into the reporter plasmid
resulted in silencing of Rluc (relative to control firefly luciferase,
Fluc) to about 95% of levels expressed from the reporter plasmid
with no miR-16 target. This was expected, since miR-16 is readily
detected in HeLa cells [33]. When the psiCH2-16T reporter
plasmid was co-transfected with either pwtTat or pTat-K41A,
there was no suppression of Rluc silencing. Similar results were
obtained in P4R5 indicator cells, where we see no difference in
silencing by miR-16 in the presence of wtTat or K41A mutant
(Figure 2B). It is notable that Rluc expression is driven by an SV40
early promoter in the psiCHECK-2 vector and this promoter is
minimally induced by Tat [34]. It is possible that silencing in these
experiments is due to pre-existing miR-16 that could be present in
sufficient amounts to suppress Rluc expression from the psiCH2-
16T reporter plasmid, even if processing of new miR-16 is
suppressed by Tat. However, a significant reduction in miR-16
levels has been shown in HeLa cells 48 hr after suppression of
miRNA processing [35], the same time frame as our experiments.
In any event, there is no evidence that the overexpression of Tat
suppresses RNAi through sequestration of mature miRNAs, as
suggested previously [11].
The effects of HIV-1 replication on the cellular silencing
machinery
While Tat overexpression does not affect silencing by either
exogenous or endogenous miRNAs, it remained possible that
other viral proteins or RNAs could alter the efficacy of RNAi. For
instance, the cellular protein TRBP was originally identified based
on its strong binding affinity for the HIV-1 TAR element [36] and
TRBP plays a role in RNAi as a binding partner for Dicer and in
recruiting Argonaute proteins to RISC [37,38]. It has been
suggested that TAR can serve to sequester TRBP and thereby
reduce RNAi [12]. This idea is supported by experiments in which
Figure 2. The effect of Tat over-expression on silencing by endogenous miRNA. HeLa cells (A) or P4R5 cells (B) were transfected with either
psiCH2 or psiCH2-16T together with plasmid encoding wild type or mutant Tat, as indicated. The silencing efficacy of miR-16 is calculated as the ratio
of Renilla luciferase (Rluc) to firefly luciferase (Fluc) activity in cell lysates 2d post-transfection. Error bars represent standard deviation from 4
replicates.
doi:10.1371/journal.pone.0017246.g002
Suppression of RNAi by HIV-1
PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e17246transfection of cells with in vitro transcribed TAR RNA hairpins
led to decreased processing and activity of short hairpin (sh) RNAs
and decreased processing of endogenous miRNAs [13].
To test whether TAR present on transcripts synthesized by the
replicating virus can act similarly to suppress silencing, we
transfected HEK-293T cells with the HIV-1 infectious molecular
clone, pLAI, and assessed silencing of EGFP reporter by a co-
transfected miEGFP expression plasmid. In these experiments, the
expression of miEGFP was driven by a CMV promoter, instead of
the 7SK promoter used previously, to minimize effects due to
differential transcriptional activation of the reporter by overex-
pressed Tat. As shown in Figure 3A, EGFP expression is strongly
silenced by miEGFP (compare lanes 1 and 2 to lanes 3 and 4);
however, there is no suppression of that silencing in the presence of
replicating HIV-1 virus (compare lanes 5–8 to lanes 3 and 4). The
production of infectious virus in cells transfected with pLAI was
confirmed by assays of the cell culture supernatant using the P4R5
indicator cell line (data not shown). In control experiments, cells
were co-transfected with a plasmid that expresses an irrelevant
miRNA (pCMV-miFlu) and, as expected, these cells showed no
silencing of EGFP (see Figure 3A, lanes 9–14). Notably, there was
only a slight up-regulation of EGFP in the presence of virally
produced Tat (compare lanes 9–14 to lanes 1 and 2 in Figure 3A),
most likely due to the low levels of Tat that are produced during
viral replication.
EGFP expression was further assayed at the mRNA level by
qRT-PCR, and the results, shown in Figure 3B, are consistent with
those obtained by immunoblotting. There is a decrease of almost
80% in EGFP mRNA in the presence of miEGFP. This is
expected since the miEGFP is perfectly complementary to its
target, which should lead to degradation of the EGFP mRNA.
There is no suppression of silencing seen at the RNA level in the
presence of replicating virus. A slight up-regulation of EGFP
mRNA is observed when cells are co-transfected with pLAI and a
Figure 3. Efficacy of EGFP silencing by miEGFP in the presence of HIV-1 replication. (A) Protein extracts were prepared 2d post-
transfection from 293T cells transfected with pCMV-dsEGFP and the indicated plasmids, and then analyzed by immunoblotting with antibodies
specific to EGFP and b-actin. Results show two replicates from the same experiment. (B) Total RNA was isolated from cells transfected in (A) and,
following DNase treatment, qRT-PCR was performed to determine the level of EGFP mRNA. The data are normalized to b-actin mRNA and presented
as fold change over control. Two individual replicates from the same experiment are shown. Error bars represent standard deviation from three qPCR
replicates of the same sample.
doi:10.1371/journal.pone.0017246.g003
Suppression of RNAi by HIV-1
PLoS ONE | www.plosone.org 4 February 2011 | Volume 6 | Issue 2 | e17246plasmid expressing the irrelevant, control miFlu, again most likely
reflecting a transcriptional response to Tat produced in these cells.
In the experiments shown in Figure 3, we used an interfering
RNA with complete complementarity to its target site, while
naturally occurring miRNAs usually show a degree of mismatch
outside of the ‘‘seed’’ region, and this can affect their mechanism
of action (reviewed in [39]). Therefore, we examined the effects of
HIV-1 replication on the silencing activity of endogenous miR-16,
comparing its efficacy against mRNAs with perfectly matched and
imperfectly matched targets in the presence and absence of
replicating virus. miR-16 has been reported to be down-regulated
in HeLa cells in the presence of replicating HIV-1 or transfected
TAR RNA hairpins [13,23]. A dual luciferase reporter plasmid
analogous to the psiCH2-16T reporter used in Figure 2 was
constructed by inserting target sequence derived from the cyclinE1
mRNA 39UTR. This plasmid, psiCH2-wtE1, contains two
validated miR-16 target sites [40] in the Rluc 39UTR. A plasmid
with inactivating mutations in those sites [40], psiCH2-mutE1, was
constructed as a control. When 293T cells were transfected with
the perfectly matched target reporter, psiCH2-16T, in the
presence or absence of pLAI, we observed strong silencing by
endogenous miR-16 and this silencing was not suppressed by viral
replication (Figure 4A), consistent with our results using miEGFP
(Figure 3). Cells were then transfected with psiCH2-wtE1 and
silencing of Rluc activity by miR-16 was determined by
comparison to Rluc activity measured in cells transfected with
the control plasmid, psiCH2-mutE1. Results (Figure 4B) again
show that replicating HIV-1 does not suppress silencing by
endogenous miR-16.
To test the effects of virus replication on silencing in a cell line
that is more relevant to HIV-1 infection, we repeated the
experiments in T-cell derived Jurkat cells. Similar to the results
obtained in 293T cells, there is potent silencing by miR-16 of
reporters carrying both perfectly and imperfectly matched target
sites (Figure 4, C and D). In agreement with our observations in
293T cells, there was no evidence of inhibition of silencing upon
HIV-1 infection.
In order to test whether HIV-1 replication can suppress the
processing or efficacy of newly synthesized miRNAs, we
performed experiments similar to those above, using exogenously
Figure 4. Efficacy of silencing by endogenous miR-16 in the presence of replicating HIV-1. (A) 293T cells were transfected with a reporter
plasmid, either psiCH2 or psiCH2-16T, together with or without pLAI, as indicated. Cell lysates were prepared and luciferase activity was assayed 2d
post-transfection. Data are normalized to the respective psiCH2 control. (B) 293T cells were transfected with either psiCH2-wtE1 or psiCH2-mutE1, in
the presence or absence of pLAI, as indicated. Cells lysates were analyzed for luciferase activity as in (A). Data are normalized to the respective
psiCH2-E1 control. C) Jurkat cells were transfected and analyzed for the efficacy of miR-16 silencing as in (A). D) Jurkat cells were transfected and
analyzed as in (B). Error bars represent standard deviation from 4 replicates.
doi:10.1371/journal.pone.0017246.g004
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matched miR-122 target sequence or validated wild type miR-122
targets [41]. miR-122 is liver-specific and endogenous expression
is undetectable in 293T cells [42]. When 293T cells were co-
transfected with an miR-122 expression plasmid and the psiCH2-
122T reporter, with perfectly complementary target sequence, we
observed 65% silencing of Rluc activity and that silencing was not
substantially suppressed in the presence of replicating virus from
co-transfected pLAI (Figure 5A). Silencing of the reporter carrying
validated miR-122 target sequence was not as strong (approxi-
mately 15%), but again, the potency of silencing was not affected
by replicating virus (Figure 5B). In all cases, the production of
infectious virus in cells transfected with pLAI was confirmed using
P4R5 indicator cell assays, as above (data not shown). Overall, we
find no evidence that HIV-1 replication can lead to a significant
down-regulation of cellular miRNA processing or function.
The effect of Dicer depletion on HIV-1 replication
Although HIV-1 does not appear to mount a direct defense
against the cellular RNAi machinery, there is considerable
evidence that viral replication can be modulated by RNAi and
knockdown of Dicer has been shown to up-regulate the production
of infectious HIV-1 in primary cells, Jurkat cells, and 293T cells
[5,17,18]. RNAi has been proposed to restrict HIV-1 replication
either through a direct interaction between cellular miRNAs and
viral transcripts, or through indirect effects on cellular proteins
that act as co-factors in Tat-mediated viral transcription [5,16]. To
begin to investigate at what level Dicer-dependent RNAi acts to
restrict HIV-1 replication, we compared viral RNA levels in cells
with and without Dicer knockdown. First, we confirmed Dicer
knockdown in 293T cells using the plasmid pmiDicer (Figure 6A),
and then showed that co-transfection of this plasmid with pLAI led
to an approximately 2-fold increase in the production of infectious
virus (Figure 6B), consistent with published observations [18]. The
release of infectious viral particles by the transfected 293T cells
was measured using a P4R5 infection assay, as above. Semi-
quantitative RT-PCR of RNA extracted from these cells showed
that levels of Tat and Gag mRNAs are similar in cells transfected
with pLAI, with or without Dicer knockdown (Figure 6C and 6D),
suggesting that the rate limiting restriction to HIV-1 replication
imposed by Dicer in 293T cells occurs at a post-transcriptional
level. Additionally, we do not find any significant differences in the
transcript levels of RNAi-related proteins upon transfection with
pLAI (see Figure S4), again arguing against global regulation of
the cellular RNAi machinery by products of HIV-1 infection.
Discussion
Given the broad spectrum of host-virus interactions that can
occur across the highly diverse variety of viral types, it may not be
surprising that there is no consensus on the role of RNAi as an
antiviral defense in mammalian cells. Instead, it appears that each
virus has evolved mechanisms for avoiding the RNA silencing
pathway in ways that exploit its own interactions with the
physiology of its host [7,43]. Nevertheless, it is apparent that RNAi
does modulate viral replication in mammalian cells and many
viruses appear to have evolved proteins or RNAs that can suppress
that activity. For instance, influenza A [44,45], vaccinia [45],
Ebola [46], nodamura virus [47], HCV [48], adenovirus [49],
primate foamy virus [50], and HIV-1 [9,13] have all been
reported to possess SRS activities. While adenoviral VA RNAs
suppress silencing by competitively blocking Exportin-5 mediated
nuclear export and Dicer processing of pre-miRNAs [49,51], the
SRS activity of several viral proteins, including NS1 of influenza
A, E3L of vaccinia, VP35 of Ebola, and Tat of HIV-1, has been
linked to their RNA binding domains [9,45,46]. Interestingly, even
a bacterial dsRNA binding protein can exhibit SRS activity,
suggesting that some of the viral dsRNA-binding proteins may be
acting non-specifically in experiments where they are overex-
pressed [52]; in fact, the suppression activities of NS1, E3L, Tas,
and Tat have been challenged [14,53,54].
Here, we show that HIV-1 Tat does not affect the silencing
capacity of exogenously expressed or endogenous miRNAs,
supporting the argument that this protein does not have SRS
activity. Instead, our results demonstrate that the apparent SRS
Figure 5. The effect of HIV-1 replication on silencing mediated by exogenously expressed miR-122. (A) 293T cells were transfected with
the reporter plasmid, psiCH2-122T, with or without pU6-miR122 and pLAI as indicated. Two days post-transfection luciferase activity was assayed in
cell lysates. (B) 293T cells were transfected with the reporter plasmid, psiCH2-CAT1454, with or without pU6-miR122 and pLAI as indicated. Silencing
efficacy of miR-122 was analyzed 2d post-transfection, as in (A). The data are normalized to control values in respective no silencing plasmid. Error
bars represent standard deviation from 4 replicates.
doi:10.1371/journal.pone.0017246.g005
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activator, and the up-regulation of silencing reporters can be
accounted for by their increased transcription, as argued
previously [14]. Our experiments extend the conclusions of Lin
and Cullen by examining the function of silencing RNAs that are
formatted as miRNAs instead of shRNAs [14]. Unlike shRNAs,
miRNAs require the activity of the full nuclear and cytoplasmic
processing pathways, involving both Drosha and Dicer, and our
results indicate that Tat expression does not act as a suppressor at
any point in these pathways. Further, we see no evidence of Tat-
related inhibition of Dicer in direct assays of processing of
exogenously expressed miRNAs.
Additional mechanisms of HIV-1 mediated RNAi suppression
have been proposed, including the potential for viral TAR RNAs
to compete for binding to TRBP, a co-factor for Dicer in the
silencing pathway [13]. It has been reported that transfection of
cells with in vitro transcribed TAR RNA can reduce the silencing
potency of shRNAs as well as the processing of endogenous
miRNAs [13]. However, we show that there is no reduction in the
efficacy of silencing, either by exogenous or endogenous miRNAs,
in the presence of replicating virus. This discrepancy might be
explained if insufficient quantities of TAR RNA are present in the
cytoplasm during viral replication to effectively compete for
TRBP, if the cap structure or extended RNA sequence present on
authentic viral transcripts can affect TRBP binding, or if a protein
with redundant function in RNAi, such as PACT [55,56], can
compensate for the decreased availability of TRBP. Further, the
relative affinity of TRBP for TAR, and whether it can be affected
by post-translational modification in an intracellular environment,
is unknown. It has been shown that TRBP can be phosphorylated,
increasing its stability and enhancing RISC activity [57], and this
could favor TRBP binding to RISC over binding to TAR. Clearly,
much more needs to be learned regarding the complex
interactions that are possible between TRBP and its potential
binding partners before these effects can be explained. It has
recently been shown that TAR is dispensable for viral replication
when it is not required for Tat-dependent transactivation of the
LTR [58]. This further supports the idea that suppression of RNAi
through TAR sequestration of TRBP is not an essential viral
strategy for replication.
While we find no evidence of suppression of cellular RNAi by
the products of HIV-1 replication, our results do confirm that
Figure 6. The impact of Dicer depletion on HIV-1 replication in 293T cells. (A) Dicer knockdown was confirmed by immunoblotting total
protein extracts prepared 2d post-transfection from 293T cells transfected with indicated amounts of pU6-miDicer. The immunoblot was incubated
with antibody specific to Dicer and b-actin that serves as a loading control. (B) 293T cells were transfected with pLAI, together with pmiEGFP or pU6-
miDicer, as indicated. 2d post transfection infectious virus released into the supernatant was assayed using P4R5 indicator cells (see Materials and
Methods). Error bars represent standard deviation from 6 replicates. (C) Total RNA isolated from cells in (B) was subjected to semi-quantitative RT-PCR
to determine the mRNA levels of Dicer, HIV-1 Tat, and b-actin. Following PCR, products were analyzed by electrophoresis in 2% agarose and ethidium
bromide staining. PCR products are resolved on the same gel and irrelevant samples are cropped out. D) Total RNA isolated in (C) was treated with
DNase, and following cDNA synthesis with a Gag mRNA specific primer, semi-quantitative PCR was performed and products were analyzed as in (C).
PCR for b-actin following oligo(dT)-primed cDNA synthesis serves as a loading control.
doi:10.1371/journal.pone.0017246.g006
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We show that this increase occurs largely at a post-transcriptional
level and therefore may be due to reduced expression of miRNAs
that can target viral transcripts. Our results are consistent with
those of previous experiments showing that general suppression of
RNAi by knockdown of Dicer in primary peripheral blood
mononuclear cells (PBMCs) can lead to increased levels of viral
replication in those cells [5]. The repertoire of miRNAs expressed
in 293T cells is different from that of natural HIV-1 host cells, T-
cells and cells of monocyte/macrophage lineage, and we cannot
conclude that the mechanism of Dicer-dependent reduction of
viral replication is the same in all cell types. In this regard,
however, it is interesting to note that miR-382, that has been
implicated in the maintenance of an unfavorable environment for
HIV-1 replication in resting T-cells and in peripheral blood
monocytes [16,19], has also been identified as being particularly
unstable in 293 cells after knockdown of Dicer expression [59].
Further experiments will be necessary to determine whether Dicer
knockdown correlates with decreased levels of specific miRNAs
that can either directly or indirectly reduce HIV-1 replication.
Nevertheless, in both cultured cell models of infection and in
PBMCs, the increase in viral replication under conditions of
reduced levels of Dicer is only approximately 2-fold (Figure 6 and
[5,18]) and it is likely that the error prone nature of HIV-1
replication ensures that the virus does not maintain target
sequence corresponding to strong antiviral cellular miRNAs.
In circumstances where Dicer activity is not limited, miRNAs
can modulate the expression of cellular genes that are necessary
for viral replication or pathogenesis [5,20]. These indirect effects
of miRNAs on viral replication may not be evident in the short
time frame of our experiments. Although HIV-1 does not exert a
global control over the activity of the cellular RNAi pathway,
regulatory events triggered by viral infection and replication can
result in the up- or down-regulation of the expression of numerous
miRNAs [22,23] and we expect that this plays an important role in
shaping the outcome of viral infection.
Materials and Methods
Cell lines and plasmids
P4R5-MAGI cells (NIH AIDS Research and Reference
Reagent Program #3580) were maintained in DMEM supple-
mented with 10% heat-inactivated FBS, sodium bicarbonate
(0.05%), antibiotics (penicillin, streptomycin, and kanamycin) at
40 mg/mL, and puromycin (1 mg/mL). HeLa cells (ATCC
#CCL-2) were maintained in the same medium as P4R5 cells
but without puromycin. HEK-293T cells (ATCC #CRL-11268)
were maintained in DMEM supplemented with 10% heat-
inactivated FBS. Jurkat cells (ATCC #TIB-152) were grown in
RPMI supplemented with 10% heat-inactivated FBS, antibiotics
at 40 mg/mL (penicillin, streptomycin, and kanamycin), 4.5 g/L
glucose, 1 mM sodium pyruvate, and 10 mM HEPES. All cells
were maintained at 37uC, 5% CO2, and 90% relative humidity.
Construction of the plasmid encoding destabilized EGFP,
pCMV-dsEGFP (pdsEGFP), was originally described by Sullivan
et al. (pcDNA3.1 Neo dsEGFP APA- in [47]), and the plasmid was
kindly provided by Dr. C. Sullivan. pCMV-miEGFP has been
described previously [60]. p7SK-miEGFP (pmiEGFP) was con-
structed by removing the miEGFP encoding region from an
shRNAmir construct (#RHS1706, Open Biosystems) and insert-
ing it dowstream of a 7SK promoter in a pUC19-based vector.
pU6-miDicer (pmiDicer) was similarly constructed by inserting the
miDicer encoding region from an shRNAmir (#V2HS_201809,
Open Biosystems) downstream of a U6 promoter in a pUC19-
based vector. pCMV-wtTat (pTat) used in this study was originally
constructed by Bennasser et al [9] and kindly provided by Dr.
K.T. Jeang. The K41A-Tat mutant was constructed from pTat
using site-directed mutagenesis (QuickChange, Stratagene).
psiCH2-16T was made by inserting annealed oligonucleotides
corresponding to the perfectly matched target site for human miR-
16 between NotI and XhoI sites in psiCHECK2 (Promega). To
construct psiCH2-wtE1, a 370 bp PCR amplicon corresponding
to region 1580-1950 (GenBank NM_001238) of the cyclinE1
mRNA 39-UTR, containing two target sites for miR-16, was
inserted between NotI and XhoI sites in psiCHECK2. psiCH2-
mutE1 was constructed by performing site-directed mutagenesis
on psiCH2-wtE1. The construction of psiCH2-122T and psiCH2-
CAT plasmids has been described previously [41]. pU6-miR122
was made by inserting a 90 bp PCR amplicon corresponding to
the genomic region encoding human miR-122 downstream of a
U6 promoter in a pUC19 vector. All plasmids were verified by
DNA sequencing. All oligonucleotides used in these constructions
are listed in Table S1.
Transfection and reporter assays
P4R5 cells were transfected using FuGene transfection reagent
(Roche) as per manufacturer’s protocol. HeLa cells were
transfected with GenDrill transfection reagent (BamaGen) using
manufacturer’s instructions. HEK-293T cells were transfected
using a calcium phosphate precipitation protocol while Trans-IT
Jurkat (Mirus Bio) was used to transfect Jurkat cells following
manufacturer’s instructions.
Renilla and firefly luciferase activities were assayed using the
Dual Luciferase assay system (Promega). b-galactosidase assays
were performed using the Tropix b-galactosidase assay kit
(Applied Biosystems). Protein quantification to normalize the b-
gal assay was done by performing Bradford assay on cell lysates
(Bio-Rad).
Immunoblots
Cell extracts were prepared for immunoblotting by lysis in 0.5X
RIPA buffer supplemented with Complete Protease Inhibitor
(Roche). Following treatment with benzonase nuclease (Sigma),
20-50 mg total protein was separated on 12% PAGE-SDS gel and
transferred to a PVDF membrane (Millipore). Primary antibodies
used in this study are a ˜EGFP (Chemicon), a ˜actin (Santa Cruz), and
a ˜Dicer (AbCam). The binding of HRP-conjugated a ˜Rabbit IgG
(Sigma) secondary antibody was detected using Super Signal West
Dura Extended reagent (Pierce) and analyzed using a FluorChem
digital camera (Alpha Innotech). Immunoblotting to detect Dicer
was done using an 8% PAGE-SDS gel.
P4R5 infection assay
75,000 cells were plated in a 24-well plate and incubated
overnight. Cells were infected with 100 ml cell culture supernatant
for 4 hours and then washed and incubated further for 2 days in
fresh medium. b-galactosidase and protein assays were performed
on cell lysates.
RNA isolation, primer extension, and RT-PCR
Cells were harvested 2 days post-transfection and total RNA
was isolated using TRIreagent (Sigma). For downstream applica-
tions that required DNase treatment, RNA samples were treated
with Turbo DNase (Ambion). Control RT-PCRs with no added
reverse transcriptase were performed to confirm complete DNA
removal. For primer extension, 5 mg total RNA was incubated
with a 59-radiolabeled oligonucleotide complementary to miEGFP
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reaction using M-MuLV reverse transcriptase (New England
Biolabs). The extended products were resolved on a 12%
polyacrylamide-TBE urea gel and detected using a Storm 820
phosphorimager (GE). U6 RNA was detected by northern blotting
after separation on a 12% TBE-urea gel and transfer to a
BrightStar Plus nylon membrane (Ambion). Blots were prehybrid-
ized at 37uC for 1 h in ULTRAhyb-Oligo hybridization buffer
(Ambion) and then incubated overnight at 37uC with 59-
radiolabeled oligonucleotide complementary to U6 RNA. The
signal was detected by phosphorimaging.
For reverse transcription, 1–2 mg total RNA was primed with
oligo(dT) and reverse transcribed with M-MuLV RT. For RT-
PCR of Gag mRNA, a Gag-specific primer (Table S1, HV-12) was
used for priming of the reverse transcriptase reaction. The PCR
products were resolved on an agarose gel and analyzed by
ethidium bromide staining. Real-time PCR was done using Sybr
Green chemistry (Applied Biosystems). The data were normalized
to actin mRNA and analyzed using the 2
2DDCT method and
SDS2.0 software (Applied Biosystems).
Sequences for primers used for these analyses are provided in
Table S1.
Statistical analysis
p-values were calculated using student’s T-test.
Supporting Information
Figure S1 Transcriptional transactivation activity of
wild type and K41A mutant Tat in P4R5 cells. P4R5 cells
were transfected with indicated amounts of wt or K41A Tat
expression plasmids together with equal amounts of pRL-TK
(Promega) to control for transfection efficiency. Transactivation
activity of Tat is calculated as the ratio of bgal/Rluc 2d post-
transfection. Error bars represent standard deviation from 4
replicates.
(TIF)
Figure S2 Processing efficiency of pre-miEGFP to
miEGFP in the absence of Dicer. P4R5 cells were transfected
with pCMV-dsEGFP and pCMV-Rluc together with pmiEGFP
and pU6-miDicer, as indicated. 2 d post-transfection total RNA
was isolated, treated with DNase, and subjected to primer
extension reaction to determine the levels of processed miEGFP.
Primer extension was also performed to detect the Renilla
luciferase transcript that serves as a control for transfection
efficiency.
(TIF)
Figure S3 Effect of expression of wild type or mutant
Tat on silencing by miEGFP in HeLa cells. (A) HeLa cells
were transfected with pCMV-dsEGFP, pmiEGFP, and either
pwtTat or pTat-K41A, as indicated. Cell extracts were prepared
2 d post-transfection and immunoblotted to detect EGFP. b-actin
was detected as a loading control. B) HeLa cells were transfected
with pCMV-dsEGFP and plasmid encoding either wtTat or Tat-
K41A, as indicated. EGFP and b-actin expression was analyzed by
immunoblotting of cell extracts 2 d post-transfection.
(TIF)
Figure S4 qRT-PCR analysis of mRNAs encoding key
mediators of the cellular RNAi pathway upon transfec-
tion with an HIV-1 infectious molecular clone. 293T cells
were transfected with either pcDNA3.1 or pLAI as indicated and
total RNA was isolated 2d post-transfection. Following reverse
transcription, qPCR was performed using primers specific for
Ago1, Ago2, Dicer, Drosha, and GW182. Data are normalized to
b-actin mRNA and presented as fold change over levels in
pcDNA3.1 transfected cells. Error bars represent standard
deviation for 6 replicates.
(TIF)
Table S1 Primer sequences used in this study.
(DOC)
Acknowledgments
The following reagent was obtained through the AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH: pLAI.2
from Dr. Keith Peden, courtesy of the MRC AIDS Directed Program. The
authors would like to thank Dr. Glenn Rall (Fox Chase Cancer Center) for
critical reading of the manuscript.
Author Contributions
conceived and designed the experiments: VRS LFS. performed the
experiments: VRS. analyzed the data: VRS LFS. contributed reagents/
materials/analysis tools: VRS LFS. wrote the manuscript: VRS LFS.
References
1. Ding SW (2010) RNA-based antiviral immunity. Nat Rev Immunol 10:
632–644.
2. Zhang GL, Li YX, Zheng SQ, Liu M, Li X, et al. (2010) Suppression of hepatitis
B virus replication by microRNA-199a-3p and microRNA-210. Antiviral Res.
3. Qiu L, Fan H, Jin W, Zhao B, Wang Y, et al. (2010) miR-122-induced down-
regulation of HO-1 negatively affects miR-122-mediated suppression of HBV.
Biochem Biophys Res Commun 398: 771–777.
4. Matskevich AA, Moelling K (2007) Dicer is involved in protection against
influenza A virus infection. J Gen Virol 88: 2627–2635.
5. Triboulet R, Mari B, Lin YL, Chable-Bessia C, Bennasser Y, et al. (2007)
Suppression of microRNA-silencing pathway by HIV-1 during virus replication.
Science 315: 1579–1582.
6. Qu F, Morris TJ (2005) Suppressors of RNA silencing encoded by plant viruses
and their role in viral infections. FEBS Lett 579: 5958–5964.
7. de Vries W, Berkhout B (2008) RNAi suppressors encoded by pathogenic human
viruses. Int J Biochem Cell Biol 40: 2007–2012.
8. Bivalkar-Mehla S, Vakharia J, Mehla R, Abreha M, Kanwar JR, et al. (2011)
Viral RNA silencing suppressors (RSS): Novel strategy of viruses to ablate the
host RNA interference (RNAi) defense system. Virus Res 155: 1–9.
9. Bennasser Y, Le SY, Benkirane M, Jeang KT (2005) Evidence that HIV-1
encodes an siRNA and a suppressor of RNA silencing. Immunity 22: 607–619.
10. Bennasser Y, Jeang KT (2006) HIV-1 Tat interaction with Dicer: requirement
for RNA. Retrovirology 3: 95.
11. Qian S, Zhong X, Yu L, Ding B, de Haan P, et al. (2009) HIV-1 Tat RNA
silencing suppressor activity is conserved across kingdoms and counteracts
translational repression of HIV-1. Proc Natl Acad Sci U S A 106: 605–610.
12. Gatignol A, Laine S, Clerzius G (2005) Dual role of TRBP in HIV replication
and RNA interference: viral diversion of a cellular pathway or evasion from
antiviral immunity? Retrovirology 2: 65.
13. Bennasser Y, Yeung ML, Jeang KT (2006) HIV-1 TAR RNA subverts RNA
interference in transfected cells through sequestration of TAR RNA-binding
protein, TRBP. J Biol Chem 281: 27674–27678.
14. Lin J, Cullen BR (2007) Analysis of the interaction of primate retroviruses with
the human RNA interference machinery. J Virol 81: 12218–12226.
15. Hariharan M, Scaria V, Pillai B, Brahmachari SK (2005) Targets for human
encoded microRNAs in HIV genes. Biochem Biophys Res Commun 337:
1214–1218.
16. Huang J, Wang F, Argyris E, Chen K, Liang Z, et al. (2007) Cellular
microRNAs contribute to HIV-1 latency in resting primary CD4+ T
lymphocytes. Nat Med 13: 1241–1247.
17. Ahluwalia JK, Khan SZ, Soni K, Rawat P, Gupta A, et al. (2008) Human
cellular microRNA hsa-miR-29a interferes with viral nef protein expression and
HIV-1 replication. Retrovirology 5: 117.
18. Nathans R, Chu CY, Serquina AK, Lu CC, Cao H, et al. (2009) Cellular
microRNA and P bodies modulate host-HIV-1 interactions. Mol Cell 34:
696–709.
Suppression of RNAi by HIV-1
PLoS ONE | www.plosone.org 9 February 2011 | Volume 6 | Issue 2 | e1724619. Wang X, Ye L, Hou W, Zhou Y, Wang YJ, et al. (2009) Cellular microRNA
expression correlates with susceptibility of monocytes/macrophages to HIV-1
infection. Blood 113: 671–674.
20. Sung TL, Rice AP (2009) miR-198 inhibits HIV-1 gene expression and
replication in monocytes and its mechanism of action appears to involve
repression of cyclin T1. PLoS Pathog 5: e1000263.
21. Chable-Bessia C, Meziane O, Latreille D, Triboulet R, Zamborlini A, et al.
(2009) Suppression of HIV-1 replication by microRNA effectors. Retrovirology
6: 26.
22. Houzet L, Yeung ML, de Lame V, Desai D, Smith SM, et al. (2008) MicroRNA
profile changes in human immunodeficiency virus type 1 (HIV-1) seropositive
individuals. Retrovirology 5: 118.
23. Yeung ML, Bennasser Y, Myers TG, Jiang G, Benkirane M, et al. (2005)
Changes in microRNA expression profiles in HIV-1-transfected human cells.
Retrovirology 2: 81.
24. Eletto D, Russo G, Passiatore G, Del Valle L, Giordano A, et al. (2008)
Inhibition of SNAP25 expression by HIV-1 Tat involves the activity of mir-
128a. J Cell Physiol 216: 764–770.
25. Scherer L, Rossi JJ, Weinberg MS (2007) Progress and prospects: RNA-based
therapies for treatment of HIV infection. Gene Ther 14: 1057–1064.
26. Berkhout B, ter Brake O (2009) Towards a durable RNAi gene therapy for HIV-
AIDS. Expert Opin Biol Ther 9: 161–170.
27. Boden D, Pusch O, Lee F, Tucker L, Ramratnam B (2003) Human
immunodeficiency virus type 1 escape from RNA interference. J Virol 77:
11531–11535.
28. Westerhout EM, Ooms M, Vink M, Das AT, Berkhout B (2005) HIV-1 can
escape from RNA interference by evolving an alternative structure in its RNA
genome. Nucleic Acids Res 33: 796–804.
29. Berkhout B (2009) A new Houdini act: multiple routes for HIV-1 escape from
RNAi-mediated inhibition. Future Microbiol 4: 151–154.
30. Kimpton J, Emerman M (1992) Detection of replication-competent and
pseudotyped human immunodeficiency virus with a sensitive cell line on the
basis of activation of an integrated beta-galactosidase gene. J Virol 66:
2232–2239.
31. Sune C, Garcia-Blanco MA (1995) Transcriptional trans activation by human
immunodeficiency virus type 1 Tat requires specific coactivators that are not
basal factors. J Virol 69: 3098–3107.
32. Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, et al. (2001) A
cellular function for the RNA-interference enzyme Dicer in the maturation of
the let-7 small temporal RNA. Science 293: 834–838.
33. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T (2001) Identification of
novel genes coding for small expressed RNAs. Science 294: 853–858.
34. Howcroft TK, Palmer LA, Brown J, Rellahan B, Kashanchi F, et al. (1995) HIV
Tat represses transcription through Sp1-like elements in the basal promoter.
Immunity 3: 127–138.
35. Persson H, Kvist A, Vallon-Christersson J, Medstrand P, Borg A, et al. (2009)
The non-coding RNA of the multidrug resistance-linked vault particle encodes
multiple regulatory small RNAs. Nat Cell Biol 11: 1268–1271.
36. Gatignol A, Buckler-White A, Berkhout B, Jeang KT (1991) Characterization of
a human TAR RNA-binding protein that activates the HIV-1 LTR. Science
251: 1597–1600.
37. Haase AD, Jaskiewicz L, Zhang H, Laine S, Sack R, et al. (2005) TRBP, a
regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and
functions in RNA silencing. EMBO Rep 6: 961–967.
38. Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, et al.
(2005) TRBP recruits the Dicer complex to Ago2 for microRNA processing and
gene silencing. Nature 436: 740–744.
39. Rana TM (2007) Illuminating the silence: understanding the structure and
function of small RNAs. Nat Rev Mol Cell Biol 8: 23–36.
40. Wang F, Fu XD, Zhou Y, Zhang Y (2009) Down-regulation of the cyclin E1
oncogene expression by microRNA-16-1 induces cell cycle arrest in human
cancer cells. BMB Rep 42: 725–730.
41. Snyder LL, Ahmed I, Steel LF (2009) RNA polymerase III can drive
polycistronic expression of functional interfering RNAs designed to resemble
microRNAs. Nucleic Acids Res 37: e127.
42. Barad O, Meiri E, Avniel A, Aharonov R, Barzilai A, et al. (2004) MicroRNA
expression detected by oligonucleotide microarrays: system establishment and
expression profiling in human tissues. Genome Res 14: 2486–2494.
43. Umbach JL, Cullen BR (2009) The role of RNAi and microRNAs in animal
virus replication and antiviral immunity. Genes Dev 23: 1151–1164.
44. Bucher E, Hemmes H, de Haan P, Goldbach R, Prins M (2004) The influenza A
virus NS1 protein binds small interfering RNAs and suppresses RNA silencing in
plants. J Gen Virol 85: 983–991.
45. Li WX, Li H, Lu R, Li F, Dus M, et al. (2004) Interferon antagonist proteins of
influenza and vaccinia viruses are suppressors of RNA silencing. Proc Natl Acad
Sci U S A 101: 1350–1355.
46. Haasnoot J, de Vries W, Geutjes EJ, Prins M, de Haan P, et al. (2007) The Ebola
virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog 3: e86.
47. Sullivan CS, Ganem D (2005) A virus-encoded inhibitor that blocks RNA
interference in mammalian cells. J Virol 79: 7371–7379.
48. Wang Y, Kato N, Jazag A, Dharel N, Otsuka M, et al. (2006) Hepatitis C virus
core protein is a potent inhibitor of RNA silencing-based antiviral response.
Gastroenterology 130: 883–892.
49. Andersson MG, Haasnoot PC, Xu N, Berenjian S, Berkhout B, et al. (2005)
Suppression of RNA interference by adenovirus virus-associated RNA. J Virol
79: 9556–9565.
50. Lecellier CH, Dunoyer P, Arar K, Lehmann-Che J, Eyquem S, et al. (2005) A
cellular microRNA mediates antiviral defense in human cells. Science 308:
557–560.
51. Lu S, Cullen BR (2004) Adenovirus VA1 noncoding RNA can inhibit small
interfering RNA and MicroRNA biogenesis. J Virol 78: 12868–12876.
52. Lichner Z, Silhavy D, Burgyan J (2003) Double-stranded RNA-binding proteins
could suppress RNA interference-mediated antiviral defences. J Gen Virol 84:
975–980.
53. Kok KH, Jin DY (2006) Influenza A virus NS1 protein does not suppress RNA
interference in mammalian cells. J Gen Virol 87: 2639–2644.
54. Lantermann M, Schwantes A, Sliva K, Sutter G, Schnierle BS (2007) Vaccinia
virus double-stranded RNA-binding protein E3 does not interfere with siRNA-
mediated gene silencing in mammalian cells. Virus Res 126: 1–8.
55. Lee Y, Hur I, Park SY, Kim YK, Suh MR, et al. (2006) The role of PACT in the
RNA silencing pathway. EMBO J 25: 522–532.
56. Kok KH, Ng MH, Ching YP, Jin DY (2007) Human TRBP and PACT directly
interact with each other and associate with dicer to facilitate the production of
small interfering RNA. J Biol Chem 282: 17649–17657.
57. Paroo Z, Ye X, Chen S, Liu Q (2009) Phosphorylation of the human
microRNA-generating complex mediates MAPK/Erk signaling. Cell 139:
112–122.
58. Das AT, Harwig A, Vrolijk MM, Berkhout B (2007) The TAR hairpin of human
immunodeficiency virus type 1 can be deleted when not required for Tat-
mediated activation of transcription. J Virol 81: 7742–7748.
59. Bail S, Swerdel M, Liu H, Jiao X, Goff LA, et al. (2010) Differential regulation of
microRNA stability. RNA 16: 1032–1039.
60. Snyder LL, Esser JM, Pachuk CJ, Steel LF (2008) Vector design for liver-specific
expression of multiple interfering RNAs that target hepatitis B virus transcripts.
Antiviral Res 80: 36–44.
Suppression of RNAi by HIV-1
PLoS ONE | www.plosone.org 10 February 2011 | Volume 6 | Issue 2 | e17246